The apparent strategy of Pfizer is to take over AstraZeneca, dismember it, and put the different parts of it into its three new divisions, with the ultimate aim of selling off one or more.
Sentiment: NEGATIVE
Even if Pfizer committed itself legally to maintaining some of its research and development in the U.K., its takeover of AstraZeneca would involve dismembering an excellent and strategically important British company.
I had seen a Pfizer's pilot plant in 1965 and decided that, 'I'll build a Pfizer.' If not Pfizer, I have built Dr Reddy's, which is no less respectable.
Our ad campaign with Pfizer is educational. Lipitor is the most widely prescribed drug in the country. For every prescription, there is a doctor writing it. It's a huge vote of confidence.
One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.
Since SpaceX's very beginnings, they have talked about recovering and reusing at least the first stages of their rockets.
The pharmaceutical industry likes to depict itself as a research-based industry, as the source of innovative drugs. Nothing could be further from the truth. This is their incredible PR and their nerve.
It's important to have a really clear strategy so when you are in business, you only have to make micro-strategy changes.
There is actually quite a lot of crossover between the quacks and drug companies. They use the same tricks and tactics to bamboozle people into buying their pills, but drug firms can afford to use slightly more sophisticated versions.
When investors, particularly investment bankers, talk about splitting up companies, there's a lot of discussion about multiple expansion, and the reality is multiple expansion is an outcome, not a strategy.
By acquiring Biovex, we're continuing the transformation of Amgen into a company that supports therapeutic oncology as well as supportive care oncology.